Linked Data API

Show Search Form

Search Results

1001919
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Rare Diseases: Drugs remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to paragraph 4.12 the UK Rare Diseases Strategy, what assessment his Department has made of whether the National Institute for Health and Care Excellence’s Single Technology Appraisal Programme meets the ambition of suitability for assessing rare disease treatments. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 188234 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-12more like thismore than 2018-11-12
star this property answer text <p>Where a company is willing to set a fair price for a drug, the National Institute for Health and Care Excellence (NICE) technology appraisal process has been proven to be suitable for the assessment of drugs for rare diseases. NICE has been able to recommend a number of drugs for patients with rare diseases through its technology appraisal programme; recent examples include dinutuximab beta for neuroblastoma and daratumumab for relapsed and refractory multiple myeloma.</p><p> </p><p>With the aim of improving the lives of all those affected by a rare disease, the United Kingdom Government published the UK Strategy for Rare Diseases in 2013, a high-level framework containing 51 commitments which sets out a seven-year strategic vision (2013-2020). The Government is committed to implementing the Strategy’s commitments and has, in January 2018, published Implementation Plans setting out its actions for England.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-12T17:23:30.543Zmore like thismore than 2018-11-12T17:23:30.543Z
unstar this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith more like this
1001918
star this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Rare Diseases: Drugs remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether officials in his Department have had discussions with the Scottish Government on the (a) Patient and Clinician Engagement system, (b) its effect on approval rates for new rare disease medicines in Scotland and (c) potential lessons from that system for NHS England. more like this
star this property tabling member constituency Bury North more like this
star this property tabling member printed
James Frith more like this
star this property uin 188233 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2018-11-14more like thismore than 2018-11-14
star this property answer text <p>Officials have had no such discussions. Health is a devolved matter and the availability of medicines for the treatment of rare diseases in Scotland is an issue for the Scottish Government.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-14T11:21:33.263Zmore like thismore than 2018-11-14T11:21:33.263Z
unstar this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4637
unstar this property label Biography information for James Frith more like this